nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—ABCB1—Levothyroxine—hypothyroidism	0.0847	0.336	CbGbCtD
Amantadine—ABCB1—Liothyronine—hypothyroidism	0.0847	0.336	CbGbCtD
Amantadine—ABCB1—Liotrix—hypothyroidism	0.0826	0.328	CbGbCtD
Amantadine—DDC—Amine-derived hormones—IYD—hypothyroidism	0.0167	0.0562	CbGpPWpGaD
Amantadine—GRIN2C—nerve—hypothyroidism	0.0161	0.0969	CbGeAlD
Amantadine—DDC—Amine-derived hormones—TPO—hypothyroidism	0.0133	0.045	CbGpPWpGaD
Amantadine—GRIN2B—nerve—hypothyroidism	0.0127	0.0766	CbGeAlD
Amantadine—GRIN2A—nerve—hypothyroidism	0.0111	0.067	CbGeAlD
Amantadine—DDC—nerve—hypothyroidism	0.0104	0.0626	CbGeAlD
Amantadine—Cardiac failure congestive—Liothyronine—hypothyroidism	0.00933	0.0326	CcSEcCtD
Amantadine—GRIN2C—CREB phosphorylation through the activation of CaMKII—NEFL—hypothyroidism	0.00915	0.0309	CbGpPWpGaD
Amantadine—GRIN2C—Unblocking of NMDA receptor, glutamate binding and activation—NEFL—hypothyroidism	0.00915	0.0309	CbGpPWpGaD
Amantadine—GRIN2D—Unblocking of NMDA receptor, glutamate binding and activation—NEFL—hypothyroidism	0.00851	0.0287	CbGpPWpGaD
Amantadine—GRIN2D—CREB phosphorylation through the activation of CaMKII—NEFL—hypothyroidism	0.00851	0.0287	CbGpPWpGaD
Amantadine—GRIN2C—Ras activation uopn Ca2+ infux through NMDA receptor—NEFL—hypothyroidism	0.00837	0.0282	CbGpPWpGaD
Amantadine—GRIN2D—Ras activation uopn Ca2+ infux through NMDA receptor—NEFL—hypothyroidism	0.00778	0.0263	CbGpPWpGaD
Amantadine—GRIN3B—testis—hypothyroidism	0.00768	0.0462	CbGeAlD
Amantadine—GRIN2A—CREB phosphorylation through the activation of CaMKII—NEFL—hypothyroidism	0.00699	0.0236	CbGpPWpGaD
Amantadine—GRIN2A—Unblocking of NMDA receptor, glutamate binding and activation—NEFL—hypothyroidism	0.00699	0.0236	CbGpPWpGaD
Amantadine—GRIN2A—Ras activation uopn Ca2+ infux through NMDA receptor—NEFL—hypothyroidism	0.00639	0.0216	CbGpPWpGaD
Amantadine—GRIN2C—adrenal cortex—hypothyroidism	0.00618	0.0372	CbGeAlD
Amantadine—DDC—Amine-derived hormones—TSHB—hypothyroidism	0.00617	0.0208	CbGpPWpGaD
Amantadine—GRIN1—Unblocking of NMDA receptor, glutamate binding and activation—NEFL—hypothyroidism	0.00609	0.0206	CbGpPWpGaD
Amantadine—GRIN1—CREB phosphorylation through the activation of CaMKII—NEFL—hypothyroidism	0.00609	0.0206	CbGpPWpGaD
Amantadine—GRIN2C—CREB phosphorylation through the activation of Ras—NEFL—hypothyroidism	0.00597	0.0201	CbGpPWpGaD
Amantadine—GRIN2B—CREB phosphorylation through the activation of CaMKII—NEFL—hypothyroidism	0.00594	0.02	CbGpPWpGaD
Amantadine—GRIN2B—Unblocking of NMDA receptor, glutamate binding and activation—NEFL—hypothyroidism	0.00594	0.02	CbGpPWpGaD
Amantadine—GRIN1—Ras activation uopn Ca2+ infux through NMDA receptor—NEFL—hypothyroidism	0.00558	0.0188	CbGpPWpGaD
Amantadine—GRIN2D—CREB phosphorylation through the activation of Ras—NEFL—hypothyroidism	0.00555	0.0187	CbGpPWpGaD
Amantadine—GRIN2B—Ras activation uopn Ca2+ infux through NMDA receptor—NEFL—hypothyroidism	0.00544	0.0183	CbGpPWpGaD
Amantadine—MAOB—nerve—hypothyroidism	0.00534	0.0322	CbGeAlD
Amantadine—Coma—Dextrothyroxine—hypothyroidism	0.00523	0.0183	CcSEcCtD
Amantadine—Coma—Levothyroxine—hypothyroidism	0.00523	0.0183	CcSEcCtD
Amantadine—Arrhythmia—Liothyronine—hypothyroidism	0.00523	0.0183	CcSEcCtD
Amantadine—Hyperkinesia—Levothyroxine—hypothyroidism	0.00499	0.0175	CcSEcCtD
Amantadine—Hyperkinesia—Dextrothyroxine—hypothyroidism	0.00499	0.0175	CcSEcCtD
Amantadine—GRIN2C—Post NMDA receptor activation events—NEFL—hypothyroidism	0.00491	0.0166	CbGpPWpGaD
Amantadine—Disorientation—Levothyroxine—hypothyroidism	0.00464	0.0163	CcSEcCtD
Amantadine—Disorientation—Dextrothyroxine—hypothyroidism	0.00464	0.0163	CcSEcCtD
Amantadine—DDC—Amine-derived hormones—SLC5A5—hypothyroidism	0.00462	0.0156	CbGpPWpGaD
Amantadine—Cardiac failure congestive—Dextrothyroxine—hypothyroidism	0.00458	0.016	CcSEcCtD
Amantadine—Cardiac failure congestive—Levothyroxine—hypothyroidism	0.00458	0.016	CcSEcCtD
Amantadine—GRIN2D—Post NMDA receptor activation events—NEFL—hypothyroidism	0.00457	0.0154	CbGpPWpGaD
Amantadine—GRIN2A—CREB phosphorylation through the activation of Ras—NEFL—hypothyroidism	0.00456	0.0154	CbGpPWpGaD
Amantadine—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—NEFL—hypothyroidism	0.00453	0.0153	CbGpPWpGaD
Amantadine—DRD2—nerve—hypothyroidism	0.00451	0.0272	CbGeAlD
Amantadine—Hypertension—Liothyronine—hypothyroidism	0.0044	0.0154	CcSEcCtD
Amantadine—GRIN2C—thyroid gland—hypothyroidism	0.0043	0.0259	CbGeAlD
Amantadine—Cardiac failure—Levothyroxine—hypothyroidism	0.00426	0.0149	CcSEcCtD
Amantadine—Cardiac failure—Dextrothyroxine—hypothyroidism	0.00426	0.0149	CcSEcCtD
Amantadine—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—NEFL—hypothyroidism	0.00421	0.0142	CbGpPWpGaD
Amantadine—GRIN2A—heart—hypothyroidism	0.00413	0.0249	CbGeAlD
Amantadine—Tachycardia—Liothyronine—hypothyroidism	0.00406	0.0142	CcSEcCtD
Amantadine—GRIN1—CREB phosphorylation through the activation of Ras—NEFL—hypothyroidism	0.00398	0.0134	CbGpPWpGaD
Amantadine—Irritability—Dextrothyroxine—hypothyroidism	0.00396	0.0139	CcSEcCtD
Amantadine—Irritability—Levothyroxine—hypothyroidism	0.00396	0.0139	CcSEcCtD
Amantadine—Cardiac arrest—Levothyroxine—hypothyroidism	0.00395	0.0138	CcSEcCtD
Amantadine—Cardiac arrest—Dextrothyroxine—hypothyroidism	0.00395	0.0138	CcSEcCtD
Amantadine—Hypotension—Liothyronine—hypothyroidism	0.00388	0.0136	CcSEcCtD
Amantadine—GRIN2B—CREB phosphorylation through the activation of Ras—NEFL—hypothyroidism	0.00388	0.0131	CbGpPWpGaD
Amantadine—Coma—Liotrix—hypothyroidism	0.00385	0.0135	CcSEcCtD
Amantadine—Lightheadedness—Liotrix—hypothyroidism	0.00377	0.0132	CcSEcCtD
Amantadine—GRIN2A—Post NMDA receptor activation events—NEFL—hypothyroidism	0.00375	0.0127	CbGpPWpGaD
Amantadine—GRIN2C—testis—hypothyroidism	0.00369	0.0222	CbGeAlD
Amantadine—Hyperkinesia—Liotrix—hypothyroidism	0.00367	0.0129	CcSEcCtD
Amantadine—Dysphagia—Levothyroxine—hypothyroidism	0.00359	0.0126	CcSEcCtD
Amantadine—Dysphagia—Dextrothyroxine—hypothyroidism	0.00359	0.0126	CcSEcCtD
Amantadine—Sweating increased—Dextrothyroxine—hypothyroidism	0.0035	0.0122	CcSEcCtD
Amantadine—Sweating increased—Levothyroxine—hypothyroidism	0.0035	0.0122	CcSEcCtD
Amantadine—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—NEFL—hypothyroidism	0.00345	0.0117	CbGpPWpGaD
Amantadine—GRIN2D—testis—hypothyroidism	0.00343	0.0207	CbGeAlD
Amantadine—Disorientation—Liotrix—hypothyroidism	0.00342	0.012	CcSEcCtD
Amantadine—GRIN2C—cerebellum—hypothyroidism	0.00341	0.0205	CbGeAlD
Amantadine—Cardiac failure congestive—Liotrix—hypothyroidism	0.00337	0.0118	CcSEcCtD
Amantadine—Renal failure acute—Liotrix—hypothyroidism	0.00331	0.0116	CcSEcCtD
Amantadine—Body temperature increased—Liothyronine—hypothyroidism	0.00329	0.0115	CcSEcCtD
Amantadine—GRIN1—Post NMDA receptor activation events—NEFL—hypothyroidism	0.00327	0.011	CbGpPWpGaD
Amantadine—GRIN3A—testis—hypothyroidism	0.00322	0.0194	CbGeAlD
Amantadine—GRIN2B—Post NMDA receptor activation events—NEFL—hypothyroidism	0.00319	0.0108	CbGpPWpGaD
Amantadine—GRIN2D—cerebellum—hypothyroidism	0.00317	0.0191	CbGeAlD
Amantadine—Cardiac failure—Liotrix—hypothyroidism	0.00313	0.011	CcSEcCtD
Amantadine—SLC22A2—Amine compound SLC transporters—SLC5A7—hypothyroidism	0.00312	0.0105	CbGpPWpGaD
Amantadine—GRIN2A—adrenal gland—hypothyroidism	0.00308	0.0186	CbGeAlD
Amantadine—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—NEFL—hypothyroidism	0.00301	0.0102	CbGpPWpGaD
Amantadine—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—NEFL—hypothyroidism	0.00294	0.00991	CbGpPWpGaD
Amantadine—Irritability—Liotrix—hypothyroidism	0.00292	0.0102	CcSEcCtD
Amantadine—SLC22A1—Amine compound SLC transporters—SLC5A7—hypothyroidism	0.00291	0.00981	CbGpPWpGaD
Amantadine—Cardiac arrest—Liotrix—hypothyroidism	0.0029	0.0102	CcSEcCtD
Amantadine—DDC—adrenal gland—hypothyroidism	0.00288	0.0173	CbGeAlD
Amantadine—GRIN1—cerebellum—hypothyroidism	0.00282	0.017	CbGeAlD
Amantadine—GRIN2B—cerebellum—hypothyroidism	0.00269	0.0162	CbGeAlD
Amantadine—Dysphagia—Liotrix—hypothyroidism	0.00264	0.00924	CcSEcCtD
Amantadine—Sweating increased—Liotrix—hypothyroidism	0.00257	0.00901	CcSEcCtD
Amantadine—Arrhythmia—Levothyroxine—hypothyroidism	0.00257	0.00899	CcSEcCtD
Amantadine—Arrhythmia—Dextrothyroxine—hypothyroidism	0.00257	0.00899	CcSEcCtD
Amantadine—GRIN2A—testis—hypothyroidism	0.00255	0.0153	CbGeAlD
Amantadine—Alopecia—Dextrothyroxine—hypothyroidism	0.00254	0.00889	CcSEcCtD
Amantadine—Alopecia—Levothyroxine—hypothyroidism	0.00254	0.00889	CcSEcCtD
Amantadine—Tension—Dextrothyroxine—hypothyroidism	0.00245	0.00859	CcSEcCtD
Amantadine—Tension—Levothyroxine—hypothyroidism	0.00245	0.00859	CcSEcCtD
Amantadine—Nervousness—Levothyroxine—hypothyroidism	0.00243	0.00851	CcSEcCtD
Amantadine—Nervousness—Dextrothyroxine—hypothyroidism	0.00243	0.00851	CcSEcCtD
Amantadine—SLC22A2—Neurotransmitter Release Cycle—SLC5A7—hypothyroidism	0.00238	0.00805	CbGpPWpGaD
Amantadine—DDC—testis—hypothyroidism	0.00238	0.0143	CbGeAlD
Amantadine—GRIN2A—cerebellum—hypothyroidism	0.00235	0.0142	CbGeAlD
Amantadine—Tremor—Dextrothyroxine—hypothyroidism	0.00234	0.0082	CcSEcCtD
Amantadine—Tremor—Levothyroxine—hypothyroidism	0.00234	0.0082	CcSEcCtD
Amantadine—DDC—Amino acid and derivative metabolism—IYD—hypothyroidism	0.00232	0.00783	CbGpPWpGaD
Amantadine—Agitation—Levothyroxine—hypothyroidism	0.0023	0.00805	CcSEcCtD
Amantadine—Agitation—Dextrothyroxine—hypothyroidism	0.0023	0.00805	CcSEcCtD
Amantadine—DDC—SIDS Susceptibility Pathways—DLX2—hypothyroidism	0.00229	0.00773	CbGpPWpGaD
Amantadine—DDC—liver—hypothyroidism	0.00225	0.0136	CbGeAlD
Amantadine—SLC22A1—Neurotransmitter Release Cycle—SLC5A7—hypothyroidism	0.00222	0.0075	CbGpPWpGaD
Amantadine—Palpitations—Dextrothyroxine—hypothyroidism	0.00221	0.00774	CcSEcCtD
Amantadine—Palpitations—Levothyroxine—hypothyroidism	0.00221	0.00774	CcSEcCtD
Amantadine—Convulsion—Dextrothyroxine—hypothyroidism	0.00217	0.00759	CcSEcCtD
Amantadine—Convulsion—Levothyroxine—hypothyroidism	0.00217	0.00759	CcSEcCtD
Amantadine—SIGMAR1—adrenal cortex—hypothyroidism	0.00214	0.0129	CbGeAlD
Amantadine—Anxiety—Levothyroxine—hypothyroidism	0.00212	0.00743	CcSEcCtD
Amantadine—Anxiety—Dextrothyroxine—hypothyroidism	0.00212	0.00743	CcSEcCtD
Amantadine—SIGMAR1—heart—hypothyroidism	0.00207	0.0125	CbGeAlD
Amantadine—Confusional state—Levothyroxine—hypothyroidism	0.00206	0.00721	CcSEcCtD
Amantadine—Confusional state—Dextrothyroxine—hypothyroidism	0.00206	0.00721	CcSEcCtD
Amantadine—MAOB—adrenal cortex—hypothyroidism	0.00205	0.0124	CbGeAlD
Amantadine—Tachycardia—Dextrothyroxine—hypothyroidism	0.00199	0.00698	CcSEcCtD
Amantadine—Tachycardia—Levothyroxine—hypothyroidism	0.00199	0.00698	CcSEcCtD
Amantadine—MAOB—heart—hypothyroidism	0.00198	0.012	CbGeAlD
Amantadine—GRIN2C—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.00198	0.00667	CbGpPWpGaD
Amantadine—Hyperhidrosis—Levothyroxine—hypothyroidism	0.00197	0.00691	CcSEcCtD
Amantadine—Hyperhidrosis—Dextrothyroxine—hypothyroidism	0.00197	0.00691	CcSEcCtD
Amantadine—GRIN1—SIDS Susceptibility Pathways—DLX2—hypothyroidism	0.00197	0.00664	CbGpPWpGaD
Amantadine—Arrhythmia—Liotrix—hypothyroidism	0.00189	0.00661	CcSEcCtD
Amantadine—MAOB—cardiovascular system—hypothyroidism	0.00187	0.0113	CbGeAlD
Amantadine—Alopecia—Liotrix—hypothyroidism	0.00187	0.00654	CcSEcCtD
Amantadine—DDC—Amino acid and derivative metabolism—TPO—hypothyroidism	0.00186	0.00626	CbGpPWpGaD
Amantadine—Insomnia—Levothyroxine—hypothyroidism	0.00185	0.00646	CcSEcCtD
Amantadine—Insomnia—Dextrothyroxine—hypothyroidism	0.00185	0.00646	CcSEcCtD
Amantadine—GRIN2D—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.00184	0.0062	CbGpPWpGaD
Amantadine—GRIN2B—ErbB4 signaling events—PRL—hypothyroidism	0.00183	0.00616	CbGpPWpGaD
Amantadine—Dyspnoea—Levothyroxine—hypothyroidism	0.00182	0.00637	CcSEcCtD
Amantadine—Dyspnoea—Dextrothyroxine—hypothyroidism	0.00182	0.00637	CcSEcCtD
Amantadine—Tension—Liotrix—hypothyroidism	0.00181	0.00632	CcSEcCtD
Amantadine—Nervousness—Liotrix—hypothyroidism	0.00179	0.00626	CcSEcCtD
Amantadine—Fatigue—Dextrothyroxine—hypothyroidism	0.00176	0.00616	CcSEcCtD
Amantadine—Fatigue—Levothyroxine—hypothyroidism	0.00176	0.00616	CcSEcCtD
Amantadine—Vision blurred—Liotrix—hypothyroidism	0.00173	0.00607	CcSEcCtD
Amantadine—SIGMAR1—pituitary gland—hypothyroidism	0.00173	0.0104	CbGeAlD
Amantadine—Tremor—Liotrix—hypothyroidism	0.00172	0.00603	CcSEcCtD
Amantadine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—NEFL—hypothyroidism	0.00169	0.00572	CbGpPWpGaD
Amantadine—Agitation—Liotrix—hypothyroidism	0.00169	0.00592	CcSEcCtD
Amantadine—Feeling abnormal—Levothyroxine—hypothyroidism	0.00168	0.00589	CcSEcCtD
Amantadine—Feeling abnormal—Dextrothyroxine—hypothyroidism	0.00168	0.00589	CcSEcCtD
Amantadine—SLC22A1—blood—hypothyroidism	0.00167	0.0101	CbGeAlD
Amantadine—GRIN1—EPH-Ephrin signaling—CLTC—hypothyroidism	0.00167	0.00563	CbGpPWpGaD
Amantadine—MAOB—pituitary gland—hypothyroidism	0.00166	0.00999	CbGeAlD
Amantadine—GRIN2B—EPH-Ephrin signaling—CLTC—hypothyroidism	0.00163	0.00549	CbGpPWpGaD
Amantadine—Palpitations—Liotrix—hypothyroidism	0.00163	0.00569	CcSEcCtD
Amantadine—Body temperature increased—Dextrothyroxine—hypothyroidism	0.00161	0.00565	CcSEcCtD
Amantadine—Body temperature increased—Levothyroxine—hypothyroidism	0.00161	0.00565	CcSEcCtD
Amantadine—Convulsion—Liotrix—hypothyroidism	0.00159	0.00558	CcSEcCtD
Amantadine—Hypertension—Liotrix—hypothyroidism	0.00159	0.00556	CcSEcCtD
Amantadine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—NEFL—hypothyroidism	0.00158	0.00531	CbGpPWpGaD
Amantadine—Anxiety—Liotrix—hypothyroidism	0.00156	0.00546	CcSEcCtD
Amantadine—SIGMAR1—adrenal gland—hypothyroidism	0.00155	0.00932	CbGeAlD
Amantadine—SIGMAR1—blood—hypothyroidism	0.00155	0.00932	CbGeAlD
Amantadine—GRIN2C—Neuronal System—SLC5A7—hypothyroidism	0.00151	0.00511	CbGpPWpGaD
Amantadine—Confusional state—Liotrix—hypothyroidism	0.00151	0.0053	CcSEcCtD
Amantadine—GRIN2A—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.00151	0.00509	CbGpPWpGaD
Amantadine—Oedema—Liotrix—hypothyroidism	0.0015	0.00526	CcSEcCtD
Amantadine—Anaphylactic shock—Liotrix—hypothyroidism	0.0015	0.00526	CcSEcCtD
Amantadine—SIGMAR1—thyroid gland—hypothyroidism	0.00149	0.00899	CbGeAlD
Amantadine—MAOB—adrenal gland—hypothyroidism	0.00148	0.00892	CbGeAlD
Amantadine—MAOB—blood—hypothyroidism	0.00148	0.00892	CbGeAlD
Amantadine—DDC—SIDS Susceptibility Pathways—THRB—hypothyroidism	0.00148	0.00498	CbGpPWpGaD
Amantadine—Tachycardia—Liotrix—hypothyroidism	0.00147	0.00513	CcSEcCtD
Amantadine—Asthenia—Dextrothyroxine—hypothyroidism	0.00146	0.00513	CcSEcCtD
Amantadine—Asthenia—Levothyroxine—hypothyroidism	0.00146	0.00513	CcSEcCtD
Amantadine—Hyperhidrosis—Liotrix—hypothyroidism	0.00145	0.00508	CcSEcCtD
Amantadine—Pruritus—Dextrothyroxine—hypothyroidism	0.00144	0.00506	CcSEcCtD
Amantadine—Pruritus—Levothyroxine—hypothyroidism	0.00144	0.00506	CcSEcCtD
Amantadine—SIGMAR1—female gonad—hypothyroidism	0.00144	0.00869	CbGeAlD
Amantadine—Anorexia—Liotrix—hypothyroidism	0.00143	0.00501	CcSEcCtD
Amantadine—MAOB—thyroid gland—hypothyroidism	0.00143	0.00861	CbGeAlD
Amantadine—GRIN2D—Neuronal System—SLC5A7—hypothyroidism	0.00141	0.00475	CbGpPWpGaD
Amantadine—Hypotension—Liotrix—hypothyroidism	0.0014	0.00491	CcSEcCtD
Amantadine—DRD2—pituitary gland—hypothyroidism	0.0014	0.00843	CbGeAlD
Amantadine—Diarrhoea—Levothyroxine—hypothyroidism	0.0014	0.00489	CcSEcCtD
Amantadine—Diarrhoea—Dextrothyroxine—hypothyroidism	0.0014	0.00489	CcSEcCtD
Amantadine—MAOB—female gonad—hypothyroidism	0.00138	0.00832	CbGeAlD
Amantadine—Insomnia—Liotrix—hypothyroidism	0.00136	0.00475	CcSEcCtD
Amantadine—Paraesthesia—Liotrix—hypothyroidism	0.00135	0.00472	CcSEcCtD
Amantadine—Dyspnoea—Liotrix—hypothyroidism	0.00134	0.00469	CcSEcCtD
Amantadine—GRIN1—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.00132	0.00444	CbGpPWpGaD
Amantadine—SLC22A1—liver—hypothyroidism	0.00131	0.00789	CbGeAlD
Amantadine—Decreased appetite—Liotrix—hypothyroidism	0.00131	0.00457	CcSEcCtD
Amantadine—Vomiting—Dextrothyroxine—hypothyroidism	0.0013	0.00454	CcSEcCtD
Amantadine—Vomiting—Levothyroxine—hypothyroidism	0.0013	0.00454	CcSEcCtD
Amantadine—Fatigue—Liotrix—hypothyroidism	0.00129	0.00453	CcSEcCtD
Amantadine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—NEFL—hypothyroidism	0.00129	0.00436	CbGpPWpGaD
Amantadine—Rash—Levothyroxine—hypothyroidism	0.00129	0.00451	CcSEcCtD
Amantadine—Rash—Dextrothyroxine—hypothyroidism	0.00129	0.00451	CcSEcCtD
Amantadine—Dermatitis—Levothyroxine—hypothyroidism	0.00129	0.0045	CcSEcCtD
Amantadine—Dermatitis—Dextrothyroxine—hypothyroidism	0.00129	0.0045	CcSEcCtD
Amantadine—Constipation—Liotrix—hypothyroidism	0.00128	0.0045	CcSEcCtD
Amantadine—GRIN2B—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.00128	0.00433	CbGpPWpGaD
Amantadine—SIGMAR1—testis—hypothyroidism	0.00128	0.00771	CbGeAlD
Amantadine—Headache—Dextrothyroxine—hypothyroidism	0.00128	0.00448	CcSEcCtD
Amantadine—Headache—Levothyroxine—hypothyroidism	0.00128	0.00448	CcSEcCtD
Amantadine—GRIN2C—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.00127	0.0043	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—THRB—hypothyroidism	0.00127	0.00428	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—NKX2-1—hypothyroidism	0.00126	0.00427	CbGpPWpGaD
Amantadine—Feeling abnormal—Liotrix—hypothyroidism	0.00124	0.00433	CcSEcCtD
Amantadine—MAOB—testis—hypothyroidism	0.00122	0.00738	CbGeAlD
Amantadine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.00122	0.00412	CbGpPWpGaD
Amantadine—Nausea—Dextrothyroxine—hypothyroidism	0.00121	0.00425	CcSEcCtD
Amantadine—Nausea—Levothyroxine—hypothyroidism	0.00121	0.00425	CcSEcCtD
Amantadine—SIGMAR1—liver—hypothyroidism	0.00121	0.00729	CbGeAlD
Amantadine—Body temperature increased—Liotrix—hypothyroidism	0.00119	0.00416	CcSEcCtD
Amantadine—GRIN2D—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.00118	0.00399	CbGpPWpGaD
Amantadine—SIGMAR1—cerebellum—hypothyroidism	0.00118	0.00712	CbGeAlD
Amantadine—MAOB—liver—hypothyroidism	0.00116	0.00697	CbGeAlD
Amantadine—GRIN2A—Neuronal System—SLC5A7—hypothyroidism	0.00116	0.0039	CbGpPWpGaD
Amantadine—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.00114	0.00384	CbGpPWpGaD
Amantadine—MAOB—cerebellum—hypothyroidism	0.00113	0.00681	CbGeAlD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—NEFL—hypothyroidism	0.00113	0.00381	CbGpPWpGaD
Amantadine—Hypersensitivity—Liotrix—hypothyroidism	0.00111	0.00387	CcSEcCtD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—NEFL—hypothyroidism	0.0011	0.00371	CbGpPWpGaD
Amantadine—Asthenia—Liotrix—hypothyroidism	0.00108	0.00377	CcSEcCtD
Amantadine—Pruritus—Liotrix—hypothyroidism	0.00106	0.00372	CcSEcCtD
Amantadine—DRD2—testis—hypothyroidism	0.00103	0.00622	CbGeAlD
Amantadine—Diarrhoea—Liotrix—hypothyroidism	0.00103	0.0036	CcSEcCtD
Amantadine—GRIN1—Neuronal System—SLC5A7—hypothyroidism	0.00101	0.0034	CbGpPWpGaD
Amantadine—Dizziness—Liotrix—hypothyroidism	0.000993	0.00348	CcSEcCtD
Amantadine—GRIN2B—Neuronal System—SLC5A7—hypothyroidism	0.000983	0.00332	CbGpPWpGaD
Amantadine—GRIN2C—Neuronal System—NEFL—hypothyroidism	0.000976	0.00329	CbGpPWpGaD
Amantadine—GRIN2A—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000972	0.00328	CbGpPWpGaD
Amantadine—Vomiting—Liotrix—hypothyroidism	0.000955	0.00334	CcSEcCtD
Amantadine—DRD2—cerebellum—hypothyroidism	0.000955	0.00575	CbGeAlD
Amantadine—Rash—Liotrix—hypothyroidism	0.000947	0.00331	CcSEcCtD
Amantadine—Dermatitis—Liotrix—hypothyroidism	0.000946	0.00331	CcSEcCtD
Amantadine—Headache—Liotrix—hypothyroidism	0.000941	0.00329	CcSEcCtD
Amantadine—GRIN2D—Neuronal System—NEFL—hypothyroidism	0.000907	0.00306	CbGpPWpGaD
Amantadine—Nausea—Liotrix—hypothyroidism	0.000892	0.00312	CcSEcCtD
Amantadine—DDC—Amino acid and derivative metabolism—TSHB—hypothyroidism	0.000859	0.0029	CbGpPWpGaD
Amantadine—GRIN1—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000848	0.00286	CbGpPWpGaD
Amantadine—GRIN2B—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000827	0.00279	CbGpPWpGaD
Amantadine—GRIN1—EPH-Ephrin signaling—VAV3—hypothyroidism	0.000786	0.00265	CbGpPWpGaD
Amantadine—GRIN2B—EPH-Ephrin signaling—VAV3—hypothyroidism	0.000767	0.00259	CbGpPWpGaD
Amantadine—ABCB1—adrenal cortex—hypothyroidism	0.000748	0.00451	CbGeAlD
Amantadine—GRIN2A—Neuronal System—NEFL—hypothyroidism	0.000745	0.00251	CbGpPWpGaD
Amantadine—ABCB1—heart—hypothyroidism	0.000724	0.00436	CbGeAlD
Amantadine—SLC22A2—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.000684	0.00231	CbGpPWpGaD
Amantadine—ABCB1—cardiovascular system—hypothyroidism	0.000683	0.00411	CbGeAlD
Amantadine—GRIN1—Neuronal System—NEFL—hypothyroidism	0.00065	0.00219	CbGpPWpGaD
Amantadine—DDC—Amino acid and derivative metabolism—SLC5A5—hypothyroidism	0.000643	0.00217	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.000638	0.00215	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—NEFL—hypothyroidism	0.000633	0.00214	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—CLTC—hypothyroidism	0.00062	0.00209	CbGpPWpGaD
Amantadine—ABCB1—gonad—hypothyroidism	0.00062	0.00373	CbGeAlD
Amantadine—ABCB1—pituitary gland—hypothyroidism	0.000605	0.00364	CbGeAlD
Amantadine—GRIN2B—Axon guidance—CLTC—hypothyroidism	0.000605	0.00204	CbGpPWpGaD
Amantadine—DDC—SIDS Susceptibility Pathways—AVP—hypothyroidism	0.000588	0.00198	CbGpPWpGaD
Amantadine—MAOB—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000573	0.00193	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—VAV3—hypothyroidism	0.000559	0.00189	CbGpPWpGaD
Amantadine—SLC22A2—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000555	0.00187	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—VAV3—hypothyroidism	0.000545	0.00184	CbGpPWpGaD
Amantadine—ABCB1—adrenal gland—hypothyroidism	0.00054	0.00325	CbGeAlD
Amantadine—ABCB1—blood—hypothyroidism	0.00054	0.00325	CbGeAlD
Amantadine—SLC22A2—Neuronal System—SLC5A7—hypothyroidism	0.000524	0.00177	CbGpPWpGaD
Amantadine—ABCB1—thyroid gland—hypothyroidism	0.000521	0.00314	CbGeAlD
Amantadine—SLC22A1—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000517	0.00174	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—AVP—hypothyroidism	0.000505	0.0017	CbGpPWpGaD
Amantadine—ABCB1—female gonad—hypothyroidism	0.000504	0.00303	CbGeAlD
Amantadine—DRD2—Circadian rythm related genes—NKX2-1—hypothyroidism	0.000498	0.00168	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—SLC5A7—hypothyroidism	0.000489	0.00165	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—AVP—hypothyroidism	0.00048	0.00162	CbGpPWpGaD
Amantadine—SLC22A2—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.00046	0.00155	CbGpPWpGaD
Amantadine—ABCB1—testis—hypothyroidism	0.000447	0.00269	CbGeAlD
Amantadine—GRIN1—Developmental Biology—CLTC—hypothyroidism	0.000443	0.00149	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000441	0.00149	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—CLTC—hypothyroidism	0.000431	0.00146	CbGpPWpGaD
Amantadine—SLC22A1—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000428	0.00145	CbGpPWpGaD
Amantadine—DDC—Metabolism—IYD—hypothyroidism	0.000426	0.00144	CbGpPWpGaD
Amantadine—ABCB1—liver—hypothyroidism	0.000422	0.00254	CbGeAlD
Amantadine—ABCB1—cerebellum—hypothyroidism	0.000413	0.00248	CbGeAlD
Amantadine—SLC22A1—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000411	0.00139	CbGpPWpGaD
Amantadine—DDC—Metabolism—ATP5O—hypothyroidism	0.000363	0.00122	CbGpPWpGaD
Amantadine—MAOB—Metabolism—IYD—hypothyroidism	0.000359	0.00121	CbGpPWpGaD
Amantadine—DDC—Metabolism—TPO—hypothyroidism	0.000341	0.00115	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—NEFL—hypothyroidism	0.000338	0.00114	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—NEFL—hypothyroidism	0.000315	0.00106	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ATP5O—hypothyroidism	0.000305	0.00103	CbGpPWpGaD
Amantadine—MAOB—Biological oxidations—POMC—hypothyroidism	0.000304	0.00103	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—VAV3—hypothyroidism	0.000292	0.000986	CbGpPWpGaD
Amantadine—MAOB—Metabolism—TPO—hypothyroidism	0.000287	0.000968	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—VAV3—hypothyroidism	0.000285	0.000961	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000282	0.000951	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000263	0.000886	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000253	0.000853	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000234	0.000788	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000225	0.00076	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000225	0.00076	CbGpPWpGaD
Amantadine—SLC22A2—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000222	0.000748	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000218	0.000734	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—VAV3—hypothyroidism	0.000209	0.000704	CbGpPWpGaD
Amantadine—SLC22A1—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000207	0.000697	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—VAV3—hypothyroidism	0.000203	0.000686	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—TRH—hypothyroidism	0.000193	0.00065	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—IYD—hypothyroidism	0.00019	0.000643	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—AVP—hypothyroidism	0.000189	0.000639	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—IYD—hypothyroidism	0.000178	0.000599	CbGpPWpGaD
Amantadine—SLC22A2—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000175	0.000589	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—TSHR—hypothyroidism	0.000172	0.000579	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—TSHB—hypothyroidism	0.000172	0.000579	CbGpPWpGaD
Amantadine—SLC22A1—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000163	0.000549	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ATP5O—hypothyroidism	0.000162	0.000546	CbGpPWpGaD
Amantadine—DDC—Metabolism—TSHB—hypothyroidism	0.000158	0.000532	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000154	0.00052	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—TPO—hypothyroidism	0.000152	0.000514	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ATP5O—hypothyroidism	0.000151	0.000509	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—TPO—hypothyroidism	0.000142	0.000479	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3C2A—hypothyroidism	0.000141	0.000475	CbGpPWpGaD
Amantadine—MAOB—Metabolism—TSHB—hypothyroidism	0.000133	0.000448	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000133	0.000448	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000128	0.00043	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3C2A—hypothyroidism	0.000118	0.000399	CbGpPWpGaD
Amantadine—DDC—Metabolism—SLC5A5—hypothyroidism	0.000118	0.000399	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000113	0.00038	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—POMC—hypothyroidism	0.000111	0.000374	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—TRH—hypothyroidism	0.000109	0.000367	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000105	0.000354	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—IYD—hypothyroidism	0.000104	0.000351	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—AVP—hypothyroidism	0.000101	0.000341	CbGpPWpGaD
Amantadine—MAOB—Metabolism—SLC5A5—hypothyroidism	9.94e-05	0.000335	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—TRH—hypothyroidism	9.88e-05	0.000333	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—TSHB—hypothyroidism	9.7e-05	0.000327	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—TSHR—hypothyroidism	9.7e-05	0.000327	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—AVP—hypothyroidism	8.87e-05	0.000299	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ATP5O—hypothyroidism	8.85e-05	0.000298	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	8.83e-05	0.000298	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—TSHB—hypothyroidism	8.81e-05	0.000297	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—TSHR—hypothyroidism	8.81e-05	0.000297	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—TPO—hypothyroidism	8.32e-05	0.000281	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—AVP—hypothyroidism	8.27e-05	0.000279	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	7.8e-05	0.000263	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—TSHB—hypothyroidism	7.05e-05	0.000238	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CLTC—hypothyroidism	6.75e-05	0.000228	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—POMC—hypothyroidism	6.72e-05	0.000227	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—TSHB—hypothyroidism	6.57e-05	0.000222	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3C2A—hypothyroidism	6.28e-05	0.000212	CbGpPWpGaD
Amantadine—DDC—Metabolism—POMC—hypothyroidism	6.18e-05	0.000209	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	6.15e-05	0.000208	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—VAV3—hypothyroidism	5.93e-05	0.0002	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3C2A—hypothyroidism	5.86e-05	0.000198	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TRH—hypothyroidism	5.84e-05	0.000197	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AVP—hypothyroidism	5.72e-05	0.000193	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—VAV3—hypothyroidism	5.39e-05	0.000182	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—SLC5A5—hypothyroidism	5.28e-05	0.000178	CbGpPWpGaD
Amantadine—MAOB—Metabolism—POMC—hypothyroidism	5.2e-05	0.000176	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TSHB—hypothyroidism	5.2e-05	0.000175	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TSHR—hypothyroidism	5.2e-05	0.000175	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AVP—hypothyroidism	5.19e-05	0.000175	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—SLC5A5—hypothyroidism	4.92e-05	0.000166	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—AVP—hypothyroidism	4.85e-05	0.000163	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SH2B3—hypothyroidism	4.64e-05	0.000156	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—TSHB—hypothyroidism	3.85e-05	0.00013	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—POMC—hypothyroidism	3.8e-05	0.000128	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—POMC—hypothyroidism	3.45e-05	0.000116	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PRL—hypothyroidism	3.44e-05	0.000116	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3C2A—hypothyroidism	3.43e-05	0.000116	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—VAV3—hypothyroidism	3.18e-05	0.000107	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AVP—hypothyroidism	3.07e-05	0.000103	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SLC5A5—hypothyroidism	2.88e-05	9.73e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—POMC—hypothyroidism	2.76e-05	9.31e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—POMC—hypothyroidism	2.57e-05	8.68e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—POMC—hypothyroidism	2.04e-05	6.87e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IGF1—hypothyroidism	1.96e-05	6.61e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—POMC—hypothyroidism	1.51e-05	5.09e-05	CbGpPWpGaD
